Sacituzumab

DRUG2 trials

Sponsors

Icahn School of Medicine at Mount Sinai, Brigham and Women's Hospital

Conditions

Malignant Neoplasm of UterusMuscle Invasive Bladder Urothelial CarcinomaOvarian Cancer

Early Phase 1

Drug Screening Using IMD in Bladder Cancer

Not yet recruitingNCT06204614

Brigham and Women's HospitalMuscle Invasive Bladder Urothelial Carcinoma

Start: 2024-02-14End: 2025-07-01Target: 18Updated: 2024-01-12

Phase 1

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

RecruitingNCT06040970

Icahn School of Medicine at Mount SinaiMalignant Neoplasm of Uterus, Ovarian Cancer

Start: 2024-10-23End: 2027-07-01Target: 54Updated: 2025-12-02

Related Papers

A single-center, open-label, single-arm, phase I study with dose expansion cohort of sacituzumab govitecan in combination with cisplatin for patients with platinum sensitive recurrent ovarian and endometrial cancer.

Journal of Clinical Oncology2025-05-28